JERUSALEM--(BUSINESS WIRE)--Teva Pharmaceutical Industries Ltd. (NASDAQ: TEVA) announced today that the U.S. District Court for the Southern District of New York has issued a decision in its litigation over the Company’s Abbreviated New Drug Application (ANDA) to market its generic version of Eisai’s acid pump inhibitor Aciphex® (Rabeprazole Sodium) Tablets, 20 mg. The Court found Eisai’s U.S. Patent No. 5,045,552 enforceable. Teva intends to appeal this decision immediately as well as the Court’s decision granting to Eisai Summary Judgment of validity.
